Telomeres and telomerase in cancer

Carcinogenesis

Volumn 31, Issue 1, 2009, Pages 9-18

  Artandi, Steven E ^a   DePinho, Ronald A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ATM PROTEIN; BETA CATENIN; BRG1 PROTEIN; CHECKPOINT KINASE RAD3; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; DYSKERIN; I KAPPA B ALPHA; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; WNT PROTEIN;

AGING; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; COLON CANCER; DNA DAMAGE; DNA REPLICATION; DYSKERATOSIS CONGENITA; ENZYME REACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; LYMPHOMA; MALIGNANT TRANSFORMATION; MUTATOR GENE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STEM CELL; TELOMERE; TUMOR PROMOTION; ANIMAL; CELL AGING; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; NEOPLASM;

ANIMALS; CELL AGING; DYSKERATOSIS CONGENITA; GERM-LINE MUTATION; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; TELOMERASE; TELOMERE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74049111326     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp268     Document Type: Review

References (161)

1. Palm, W. et al. (2008) How shelterin protects mammalian telomeres. Annu. Rev. Genet., 42, 301-334.
2. Griffith, J.D. et al. (1999) Mammalian telomeres end in a large duplex loop. Cell, 97, 503-514.
3. van Steensel, B. et al. (1998) TRF2 protects human telomeres from end-toend fusions. Cell, 92, 401-413.
4. Celli, G.B. et al. (2005) DNA processing is not required for ATMmediated telomere damage response after TRF2 deletion. Nat. Cell Biol., 7, 712-718.
5. van Steensel, B. et al. (1997) Control of telomere length by the human telomeric protein TRF1. Nature, 385, 740-743.
6. Smogorzewska, A. et al. (2000) Control of human telomere length by TRF1 and TRF2. Mol. Cell. Biol., 20, 1659-1668.
7. Sfeir, A. et al. (2009) Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell, 138, 90-103.
8. Kim, S.H. et al. (1999) TIN2, a new regulator of telomere length in human cells. Nat. Genet., 23, 405-412.
9. de Lange, T. (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev., 19, 2100-2110.
10. Li, B. et al. (2000) Identification of human Rap1: implications for telomere evolution. Cell, 101, 471-483.
11. Bae, N.S. et al. (2007) A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends. Mol. Cell, 26, 323-334.
12. Sarthy, J. et al. (2009) Human RAP1 inhibits non-homologous end joining at telomeres. EMBO J., 28, 3390-3399.
13. Baumann, P. et al. (2001) Pot1, the putative telomere end-binding protein in fission yeast and humans. Science, 292, 1171-1175.
14. Ye, J.Z. et al. (2004) POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev., 18, 1649-1654.
15. Liu, D. et al. (2004) PTOP interacts with POT1 and regulates its localization to telomeres. Nat. Cell Biol., 6, 673-680.
16. Hockemeyer, D. et al. (2005) POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J., 24, 2667-2678.
17. Hockemeyer, D. et al. (2006) Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell, 126, 63-77.
18. Wu, L. et al. (2006) Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell, 126, 49-62.
19. Hockemeyer, D. et al. (2007) Telomere protection by mammalian Pot1 requires interaction with Tpp1. Nat. Struct. Mol. Biol., 14, 754-761.
20. Loayza, D. et al. (2003) POT1 as a terminal transducer of TRF1 telomere length control. Nature, 424, 1013-1018.
21. Wang, F. et al. (2007) The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature, 445, 506-510.
22. Xin, H. et al. (2007) TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature, 445, 559-562.
23. Hayflick, L. et al. (1961) The serial cultivation of human diploid cell strains. Exp. Cell Res., 25, 585-621.
24. Harley, C.B. et al. (1990) Telomeres shorten during ageing of human fibroblasts. Nature, 345, 458-460.
25. Shay, J.W. et al. (1991) A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res., 196, 33-39.
26. Hara, E. et al. (1991) Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun., 179, 528-534.
27. Counter, C.M. et al. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 11, 1921-1929.
28. Bodnar, A.G. et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science, 279, 349-352.
29. Counter, C.M. et al. (1998) Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl Acad. Sci. USA, 95, 14723-14728.
30. Greider, C.W. et al. (1989) A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature, 337, 331-337.
31. Lingner, J. et al. (1997) Reverse transcriptase motifs in the catalytic subunit of telomerase. Science, 276, 561-567.
32. Nakamura, T.M. et al. (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science, 277, 955-959.
33. Meyerson, M. et al. (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90, 785-795.
34. Weinrich, S.L. et al. (1997) Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet., 17, 498-502.
35. Mitchell, J.R. et al. (1999) A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3' end. Mol. Cell. Biol., 19, 567-576.
36. Chen, J.L. et al. (2000) Secondary structure of vertebrate telomerase RNA. Cell, 100, 503-514.
37. Matera, A.G. et al. (2007) Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat. Rev. Mol. Cell Biol., 8, 209-220
38. Cioce, M. et al. (2005) Cajal bodies: a long history of discovery. Annu. Rev. Cell Dev. Biol., 21, 105-131.
39. Zhu, Y. et al. (2004) Telomerase RNA accumulates in Cajal bodies in human cancer cells. Mol. Biol. Cell, 15, 81-90.
40. Jady, B.E. et al. (2004) Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal. J. Cell Biol., 164, 647-652.
41. Tomlinson, R.L. et al. (2006) Cell cycle-regulated trafficking of human telomerase to telomeres. Mol. Biol. Cell, 17, 955-965.
42. Cristofari, G. et al. (2007) Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation. Mol. Cell, 27, 882-889.
43. Mitchell, J.R. et al. (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature, 402, 551-555.
44. Cohen, S.B. et al. (2007) Protein composition of catalytically active human telomerase from immortal cells. Science, 315, 1850-1853.
45. Venteicher, A.S. et al. (2008) Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell, 132, 945-957.
46. Venteicher, A.S. et al. (2009) A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science, 323, 644-648.
47. Tycowski, K.T. et al. (2009) A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles. Mol. Cell, 34, 47-57.
48. Kim, N.W. et al. (1994) Specific association of human telomerase activity 965 with immortal cells and cancer. Science. 266, 2011-2015.
49. Yui, J. et al. (1998) Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood, 91, 3255-3262.
50. Liu, K. et al. (1999) Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc. Natl Acad. Sci. USA, 96, 5147-5152.
51. Forsyth, N.R. et al. (2002) Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation, 69, 188-197.
52. Bachor, C. et al. (1999) Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J. Cancer Res. Clin. Oncol., 125, 453-460.
53. Ramirez, R.D. et al. (1997) Telomerase activity concentrates in the mitotically active segments of human hair follicles. J. Invest. Dermatol., 108, 113-117.
54. Takahashi, K. et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
55. Breault, D.T. et al. (2008) Generation of mTert-GFP mice as a model to identify and study tissue progenitor cells. Proc. Natl Acad. Sci. USA, 105, 10420-10425.
56. Greenberg, R.A. et al. (1999) Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene, 18, 1219-1226.
57. Wu, K.J. et al. (1999) Direct activation of TERT transcription by c-MYC. Nat. Genet., 21, 220-224.
58. Kyo, S. et al. (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci., 99, 1528-1538.
59. Kim, J.H. et al. (2005) Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev., 19, 776-781.
60. Blasco, M.A. et al. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91, 25-34.
61. Lee, H.W. et al. (1998) Essential role of mouse telomerase in highly proliferative organs. Nature, 392, 569-574.
62. Hande, M.P. et al. (1999) Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J. Cell Biol., 144, 589-601.
63. Rudolph, K.L. et al. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96, 701-712.
64. Wong, K.K. et al. (2000) Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat. Genet., 26, 85-88.
65. Allsopp, R.C. et al. (2003) Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood, 102, 517-520.
66. Choudhury, A.R. et al. (2007) Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet., 39, 99-105.
67. Hemann, M.T. et al. (2001) The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell, 107, 67-77.
68. Samper, E. et al. (2001) Restoration of telomerase activity rescues chromosomal instability and premature aging in Terc-/-mice with short telomeres. EMBO Rep., 2, 800-807.
69. Krizhanovsky, V. et al. (2008) Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb. Symp. Quant.Biol., 73, 513-522.
70. Chin, L. et al. (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell, 97, 527-538.
71. Karlseder, J. et al. (1999) p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science, 283, 1321-1325.
72. Takai, H. et al. (2003) DNA damage foci at dysfunctional telomeres. Curr. Biol., 13, 1549-1556.
73. d'Adda di Fagagna, F. et al. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194-198.
74. Denchi, E.L. et al. (2007) Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature, 448, 1068-1071.
75. Guo, X. et al. (2007) Dysfunctional telomeres activate an ATM-ATRdependent DNA damage response to suppress tumorigenesis. EMBO J., 26, 4709-4719.
76. Brown, J.P. et al. (1997) Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science, 277, 831-834.
77. Herrera, E. et al. (1999) Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J., 18, 2950-2960.
78. Garinis, G.A. et al. (2008) DNA damage and ageing: new-age ideas for an age-old problem. Nat. Cell Biol., 10, 1241-1247.
79. Ayouaz, A. et al. (2008) Telomeres: hallmarks of radiosensitivity. Biochimie, 90, 60-72.
80. Tyner, S.D. et al. (2002) p53 mutant mice that display early ageingassociated phenotypes. Nature, 415, 45-53.
81. Quelle, D.E. et al. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83, 993-1000.
82. Kim, W.Y. et al. (2006) The regulation of INK4/ARF in cancer and aging. Cell, 127, 265-275.
83. Pomerantz, J. et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92, 713-723.
84. Kamijo, T. et al. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA, 95, 8292-8297.
85. Kamijo, T. et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell, 91, 649-659.
86. Serrano, M. et al. (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85, 27-37.
87. Greenberg, R.A. et al. (1999) Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell, 97, 515-525.
88. Khoo, C.M. et al. (2007) Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc. Natl Acad. Sci. USA, 104, 3931-3936.
89. Rudolph, K.L. et al. (2001) Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet., 28, 155-159.
90. Jaskelioff, M. et al. (2009) Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene.
91. Balmain, A. et al. (1984) Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature, 307, 658-660
92. Gonzalez-Suarez, E. et al. (2000) Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet., 26, 114-117.
93. Feldser, D.M. et al. (2007) Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell, 11, 461-469.
94. Cosme-Blanco, W. et al. (2007) Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep., 8, 497-503.
95. Land, H. et al. (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature, 304, 596-602
96. Hahn, W.C. et al. (1999) Creation of human tumour cells with defined genetic elements. Nature, 400, 464-468.
97. Elenbaas, B. et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev., 15, 50-65.
98. Dajee, M. et al. (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature, 421, 639-643.
99. Wu, M. et al. (2009) Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc. Natl Acad. Sci. USA, 106, 7022-7027.
100. Chang, S. et al. (2003) Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev., 17, 88-100.
101. Harvey, M. et al. (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet., 5, 225-229.
102. Jacks, T. et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4, 1-7.
103. Kastan, M.B. et al. (2004) Cell-cycle checkpoints and cancer. Nature, 432, 316-323.
104. Artandi, S.E. et al. (2000) Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature, 406, 641-645.
105. Windle, B. et al. (1991) A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev., 5, 160-174.
106. O'Hagan, R.C. et al. (2002) Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell, 2, 149-155.
107. Maser, R.S. et al. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 447, 966-971
108. Smogorzewska, A. et al. (2005) DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol, 12, 1635-44.
109. Keegan, C.E. et al. (2005) Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd) mice is caused by a splicing mutation in a novel telomeric regulator. Hum. Mol. Genet., 14, 113-123.
110. Vlangos, C.N. et al. (2009) Caudal regression in adrenocortical dysplasia (acd) mice is caused by telomere dysfunction with subsequent p53-dependent apoptosis. Dev. Biol., 334, 418-428.
111. Else, T. et al. (2009) Genetic p53deficiency partially rescues the adrenocortical dysplasia (acd) phenotype at the expense of increased tumorigenesis. Cancer Cell, 15, 465-476.
112. Armitage, P. et al. (1954) The age distribution of cancer and a multi-stage theory of carcinogensis. Br. J. Cancer, 8, 1-12.
113. Pinkel, D. et al. (2005) Array comparative genomic hybridization and its applications in cancer. Nat. Genet., 37 (suppl.), S11-S17.
114. Bardeesy, N. et al. (2001) Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol. Cell. Biol., 21, 2144-2153.
115. Donehower, L.A. et al. (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinog., 14, 16-22.
116. Hodgson, G. et al. (2001) Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat. Genet., 29, 459-464.
117. Albertson, D.G. et al. (2000) Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet., 25, 144-146.
118. Sweet-Cordero, A. et al. (2006) Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes, Chromosomes Cancer, 45, 338-348.
119. Zhu, C. et al. (2002) Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell, 109, 811-821.
120. Chadeneau, C. et al. (1995) Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res., 55, 2533-2536.
121. Engelhardt, M. et al. (1997) Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin. Cancer Res., 3, 1931-1941.
122. Odagiri, E. et al. (1994) Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer, 73, 2978-2984.
123. Meeker, A.K. et al. (2002) Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am. J. Pathol., 160, 1259-1268.
124. Meeker, A.K. et al. (2004) Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am. J. Pathol., 164, 925-935.
125. van Heek, N.T. et al. (2002) Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol., 161, 1541-1547.
126. Chin, K. et al. (2004) In situ analyses of genome instability in breast cancer. Nat. Genet., 36, 984-988.
127. Meeker, A.K. et al. (2004) Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res., 10, 3317-3326.
128. Meeker, A.K. et al. (2004) Recent advances in telomere biology: implications for human cancer. Curr. Opin. Oncol., 16, 32-38.
129. Shpitz, B. et al. (1999) Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat., 58, 65-69.
130. O'Sullivan, J.N. et al. (2002) Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet., 32, 280-284.
131. Rudolph, K.L. et al. (2000) Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science, 287, 1253-1258.
132. Miura, N. et al. (1997) Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet., 93, 56-62.
133. Urabe, Y. et al. (1996) Telomere length in human liver diseases. Liver, 16, 293-297.
134. Kitada, T. et al. (1995) Telomere shortening in chronic liver diseases. Biochem. Biophys. Res. Commun., 211, 33-39.
135. Zheng, H. et al. (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 455, 1129-1133.
136. Artandi, S.E. (2002) Telomere shortening and cell fates in mouse models of neoplasia. Trends Mol. Med., 8, 44-47.
137. Gonzalez-Suarez, E. et al. (2001) Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J., 20, 2619-2630.
138. Stewart, S.A. et al. (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl Acad. Sci. USA, 99, 12606-12611.
139. Smith, L.L. et al. (2003) Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol., 5, 474-479.
140. Armstrong, L. et al. (2005) Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells, 23, 516-529.
141. Imamura, S. et al. (2008) A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS One, 3, e3364.
142. Yang, C. et al. (2008) A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. Stem Cells, 26, 850-863.
143. Fu, W. et al. (1999) Anti-apoptotic role of telomerase in pheochromocytoma cells. J. Biol. Chem., 274, 7264-7271.
144. Lee, J. et al. (2008) TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene, 27, 3754-3760.
145. Masutomi, K. et al. (2005) The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl Acad. Sci. USA, 102, 8222-8227.
146. Sarin, K.Y. et al. (2005) Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature, 436, 1048-1052.
147. Flores, I. et al. (2005) Effects of telomerase and telomere length on epidermal stem cell behavior. Science, 309, 1253-1256.
148. Choi, J. et al. (2008) TERT promotes epithelial proliferation through transcriptional control of a Myc-and Wnt-related developmental program. PLoS Genet., 4, e10.
149. Park, J.I. et al. (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature, 460, 66-72.
150. Gat, U. et al. (1998) De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell, 95, 605-614.
151. Lo Celso, C. et al. (2004) Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development, 131, 1787-1799.
152. Van Mater, D. et al. (2003) Transient activation of beta -catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice. Genes Dev., 17, 1219-1224.
153. Maida, Y. et al. (2009) An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature, 461, 230-235.
154. Savage, S.A. et al. (2009) Dyskeratosis congenita. Hematol. Oncol. Clin. North Am., 23, 215-231.
155. Armanios, M. (2009) Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet., 10, 45-61.
156. Vulliamy, T. et al. (2001) The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature, 413, 432-435.
157. Armanios, M. et al. (2005) Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc. Natl Acad. Sci. USA, 102, 15960-15964.
158. Savage, S.A. et al. (2008) TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am. J. Hum. Genet., 82, 501-509.
159. Walne, A.J. et al. (2008) TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood, 112, 3594-3600.
160. Vulliamy, T. et al. (2008) Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc. Natl Acad. Sci. USA, 105, 8073-8078.
161. Walne, A.J. et al. (2007) Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum. Mol. Genet., 16, 1619-1629.